endocrine pharmaceuticals limited
endocrine pharmaceuticals limited Company Information
Company Number
03005721
Next Accounts
Mar 2026
Shareholders
john hart
richard douglas
View AllGroup Structure
View All
Industry
Other research and experimental development on natural sciences and engineering
Registered Address
wilderness end, tadley common road, tadley, hampshire, RG26 3TA
Website
http://endopharm.co.ukendocrine pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of ENDOCRINE PHARMACEUTICALS LIMITED at £302.9k based on a Turnover of £263.2k and 1.15x industry multiple (adjusted for size and gross margin).
endocrine pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of ENDOCRINE PHARMACEUTICALS LIMITED at £0 based on an EBITDA of £-8.7k and a 5.45x industry multiple (adjusted for size and gross margin).
endocrine pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of ENDOCRINE PHARMACEUTICALS LIMITED at £0 based on Net Assets of £-90k and 1.93x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Endocrine Pharmaceuticals Limited Overview
Endocrine Pharmaceuticals Limited is a live company located in tadley, RG26 3TA with a Companies House number of 03005721. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in January 1995, it's largest shareholder is john hart with a 24% stake. Endocrine Pharmaceuticals Limited is a mature, micro sized company, Pomanda has estimated its turnover at £263.2k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Endocrine Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded Endocrine Pharmaceuticals Limited a 0.5 rating. We use a traffic light system to show it exceeds the industry average on 0 measures and has 8 areas for improvement. Company Health Check FAQs
0 Strong
2 Regular
8 Weak
Size
annual sales of £263.2k, make it smaller than the average company (£4.4m)
- Endocrine Pharmaceuticals Limited
£4.4m - Industry AVG
Growth
3 year (CAGR) sales growth of -8%, show it is growing at a slower rate (7.5%)
- Endocrine Pharmaceuticals Limited
7.5% - Industry AVG
Production
with a gross margin of 49.9%, this company has a comparable cost of product (49.9%)
- Endocrine Pharmaceuticals Limited
49.9% - Industry AVG
Profitability
an operating margin of -3.3% make it less profitable than the average company (2%)
- Endocrine Pharmaceuticals Limited
2% - Industry AVG
Employees
with 3 employees, this is below the industry average (45)
3 - Endocrine Pharmaceuticals Limited
45 - Industry AVG
Pay Structure
on an average salary of £65.2k, the company has an equivalent pay structure (£65.2k)
- Endocrine Pharmaceuticals Limited
£65.2k - Industry AVG
Efficiency
resulting in sales per employee of £87.7k, this is less efficient (£125.1k)
- Endocrine Pharmaceuticals Limited
£125.1k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Endocrine Pharmaceuticals Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 0 days, this is quicker than average (43 days)
- Endocrine Pharmaceuticals Limited
43 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Endocrine Pharmaceuticals Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 2 weeks, this is less cash available to meet short term requirements (33 weeks)
2 weeks - Endocrine Pharmaceuticals Limited
33 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 1835.8%, this is a higher level of debt than the average (40.7%)
1835.8% - Endocrine Pharmaceuticals Limited
40.7% - Industry AVG
ENDOCRINE PHARMACEUTICALS LIMITED financials
Endocrine Pharmaceuticals Limited's latest turnover from June 2024 is estimated at £263.2 thousand and the company has net assets of -£90 thousand. According to their latest financial statements, Endocrine Pharmaceuticals Limited has 3 employees and maintains cash reserves of £5.2 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||||||||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | -20,754 | -24,573 | -19,134 | ||||||||||||
| Interest Payable | |||||||||||||||
| Interest Receivable | |||||||||||||||
| Pre-Tax Profit | -20,754 | -24,573 | -19,134 | ||||||||||||
| Tax | 1,977 | 1,284 | |||||||||||||
| Profit After Tax | -18,777 | -23,289 | -19,134 | ||||||||||||
| Dividends Paid | |||||||||||||||
| Retained Profit | -18,777 | -23,289 | -19,134 | ||||||||||||
| Employee Costs | |||||||||||||||
| Number Of Employees | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||||
| EBITDA* | -20,742 | -24,557 | -19,112 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 38 | 50 | 66 | 88 | 118 | 158 | 210 | ||||||||
| Intangible Assets | |||||||||||||||
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 38 | 50 | 66 | 88 | 118 | 158 | 210 | ||||||||
| Stock & work in progress | |||||||||||||||
| Trade Debtors | |||||||||||||||
| Group Debtors | |||||||||||||||
| Misc Debtors | |||||||||||||||
| Cash | 5,187 | 2,160 | 6,596 | 8,878 | 4,811 | 3,087 | 7,076 | 12,660 | 4,597 | 5,971 | 20,675 | 348 | 4,817 | 5,067 | 5,940 |
| misc current assets | |||||||||||||||
| total current assets | 5,187 | 2,160 | 6,596 | 8,878 | 4,811 | 3,087 | 7,076 | 12,660 | 4,597 | 5,971 | 20,675 | 348 | 4,817 | 5,067 | 5,940 |
| total assets | 5,187 | 2,160 | 6,596 | 8,878 | 4,811 | 3,087 | 7,076 | 12,660 | 4,635 | 6,021 | 20,741 | 436 | 4,935 | 5,225 | 6,150 |
| Bank overdraft | 547 | ||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 90 | 684 | 54,663 | 47,738 | 42,957 | 36,118 | |||||||||
| Group/Directors Accounts | 5,331 | 3,971 | 2,710 | 1,208 | 1,065 | ||||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 95,132 | 89,669 | 83,594 | 78,410 | 72,366 | 65,832 | 54,643 | 49,249 | 44,779 | 40,074 | 34,648 | ||||
| total current liabilities | 95,222 | 89,669 | 83,594 | 78,410 | 72,366 | 66,379 | 59,974 | 53,220 | 48,173 | 41,282 | 35,713 | 54,663 | 47,738 | 42,957 | 36,118 |
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | |||||||||||||||
| total long term liabilities | |||||||||||||||
| total liabilities | 95,222 | 89,669 | 83,594 | 78,410 | 72,366 | 66,379 | 59,974 | 53,220 | 48,173 | 41,282 | 35,713 | 54,663 | 47,738 | 42,957 | 36,118 |
| net assets | -90,035 | -87,509 | -76,998 | -69,532 | -67,555 | -63,292 | -52,898 | -40,560 | -43,538 | -35,261 | -14,972 | -54,227 | -42,803 | -37,732 | -29,968 |
| total shareholders funds | -90,035 | -87,509 | -76,998 | -69,532 | -67,555 | -63,292 | -52,898 | -40,560 | -43,538 | -35,261 | -14,972 | -54,227 | -42,803 | -37,732 | -29,968 |
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | -20,754 | -24,573 | -19,134 | ||||||||||||
| Depreciation | 38 | 12 | 16 | 22 | 30 | 40 | 52 | 70 | |||||||
| Amortisation | |||||||||||||||
| Tax | 1,977 | 1,284 | |||||||||||||
| Stock | |||||||||||||||
| Debtors | |||||||||||||||
| Creditors | 90 | -684 | 684 | -54,663 | 6,925 | 4,781 | 6,839 | 36,118 | |||||||
| Accruals and Deferred Income | 5,463 | 6,075 | 5,184 | 6,044 | 6,534 | 11,189 | 5,394 | 4,470 | 4,705 | 5,426 | 34,648 | ||||
| Deferred Taxes & Provisions | |||||||||||||||
| Cash flow from operations | -13,376 | -17,847 | -39,127 | ||||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | -5,331 | 1,360 | 1,261 | 1,502 | 143 | 1,065 | |||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | |||||||||||||||
| cash flow from financing | |||||||||||||||
| cash and cash equivalents | |||||||||||||||
| cash | 3,027 | -4,436 | -2,282 | 4,067 | 1,724 | -3,989 | -5,584 | 8,063 | -1,374 | -14,704 | 20,327 | -4,469 | -250 | -873 | 5,940 |
| overdraft | -547 | 547 | |||||||||||||
| change in cash | 3,027 | -4,436 | -2,282 | 4,067 | 2,271 | -4,536 | -5,584 | 8,063 | -1,374 | -14,704 | 20,327 | -4,469 | -250 | -873 | 5,940 |
endocrine pharmaceuticals limited Credit Report and Business Information
Endocrine Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for endocrine pharmaceuticals limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in RG26 area or any other competitors across 12 key performance metrics.
endocrine pharmaceuticals limited Ownership
ENDOCRINE PHARMACEUTICALS LIMITED group structure
Endocrine Pharmaceuticals Limited has no subsidiary companies.
Ultimate parent company
ENDOCRINE PHARMACEUTICALS LIMITED
03005721
endocrine pharmaceuticals limited directors
Endocrine Pharmaceuticals Limited currently has 3 directors. The longest serving directors include Dr John Hart (May 1995) and Mr Lyell Fairlie (Jan 2014).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr John Hart | 71 years | May 1995 | - | Director | |
| Mr Lyell Fairlie | England | 79 years | Jan 2014 | - | Director |
| Mr Gavin Douglas | England | 52 years | Jun 2020 | - | Director |
P&L
June 2024turnover
263.2k
-22%
operating profit
-8.7k
0%
gross margin
50%
+0.96%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
June 2024net assets
-90k
+0.03%
total assets
5.2k
+1.4%
cash
5.2k
+1.4%
net assets
Total assets minus all liabilities
endocrine pharmaceuticals limited company details
company number
03005721
Type
Private limited with Share Capital
industry
72190 - Other research and experimental development on natural sciences and engineering
incorporation date
January 1995
age
30
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
June 2024
previous names
kandah enterprises limited (July 1995)
accountant
BARKER WILKINSON LIMITED
auditor
-
address
wilderness end, tadley common road, tadley, hampshire, RG26 3TA
Bank
BANK OF IRELAND
Legal Advisor
-
endocrine pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to endocrine pharmaceuticals limited.
endocrine pharmaceuticals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ENDOCRINE PHARMACEUTICALS LIMITED. This can take several minutes, an email will notify you when this has completed.
endocrine pharmaceuticals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
